Abstract
Currently, treatment of intra-abdominal infections is significantly complicated by increased antimicrobial resistance. Inappropriate antimicrobial therapy is one of the reasons for spread of extended spectrum beta-lactamases (ESBL) both in hospital and outpatient settings. It was associated with significant decrease in efficacy of cephalosporins in the treatment of intra-abdominal infections. There is also a trend to increase resistance of pathogens to fluoroquinolones. In order to keep antimicrobials with activity against non-fermenting Gramnegative bacteria effective, stratification of patients with intra-abdominal infections by the risk of multidrug resistant pathogens should be performed when administering empiric antibacterial therapy.
-
1.
Савельев В.С., Гельфанд Б.Р., Филимонов М.Н. Перитонит. Практическое руководство. Москва, Литтера. 2006 г.
-
2.
Брискин Б.С., Дибиров М.Д., Хачатрян Н.Н., Карсотьян Г.С., Михайлин А.А., Фесенко Т.А.. Антибактериальная терапия у больных с тяжелыми формами распространенного перитонита. Consilium Medicum. Хирургия. 2008; (1):23-5.
-
3.
Голуб А.В., Дехнич А.В., Козлов Р.С. Антибактериальная терапия осложненных интраабдоминальных инфекций: от чего зависит успех? Клин микробиол антимикроб химиотер 2011; 13(2):1-5.
-
4.
Костюченок К.В. Прогнозирование исходов хирургического лечения распространенного перитонита. Автореф. дисс. канд. наук, 2009.
-
5.
Umgelter A., Reindl W., Miedaner M., Schmid R.M., Huber W. Failure of current antibiotic first-line regimes and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 2009; 37(1):2-8.
-
6.
Bare M. Presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, 2002.
-
7.
Davey P. Presented at the International Society of Pharmacоeconomics and Outcomes Research Sixth Annual International Meeting, Virginia, USA, 2001.
-
8.
Hawser S.P., Bouchillon S.K., Lascols C., et al. Susceptibility of European Escherichia coli clinical isolates from intraabdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clin Microbiol Infect 2011; 18:253-9.
-
9.
Brink A.J., Botha R.F., Poswa X., et al. Antimicrobial susceptibility of Gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009). Surgical Infections 2012; 13:43-9.
-
10.
Canton R., Loza E., Aznar J., et al. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002- 2010). Rev Esp Quimioter 2011; 24(4):223-32.
-
11.
Paterson D., Rossi F., Baquero F., et al. In vitro susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55:965-72.
-
12.
Krobot K., Yin D., Zhang Q., et al. Effect of inappropiate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23;682-7.
-
13.
Carmeli Y. The role of carbapanems. The predictive factors for multi-drug resistant gram-negatives. 2006.
-
14.
Козлов Р.С., Дехнич А.В. Справочник по антимикробной терапии. Выпуск 2. МАКМАХ, 2010. 415 c.
-
15.
Rodriges-Bano J., Pascual A. Clinical significance of extended-spectrum β-lactamases. Expert Rev Anti Infect Ther 2008; 6(5):671-83.
-
16.
Chi-Chang H., Yao-Shen C., Han-Siong T., et al. Impact of revised CLSI breakpoints for susceptibility to thirdgeneration cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010. Int J Antimicrob Agents 2012; 40(Suppl.):S4-10.
-
17.
Cornaglia G., Hryniewich W., Jarlier V., et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10:349-83.
-
18.
Joo E.J., Kang C.I., Ha Y.E., et al. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection 2011; 39(4):309- 18.
-
19.
Goff Debra., Mangino J. Ertapenem: Effect on Gramnegative pathogens 19 months after formulary addition. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 Dec 16-19; Washington D.C., USA.
-
20.
Goldstein E.J., Citon D.M., Peraino V. Effect on antimicrobial usage and the in vitro susceptibility on aerobic gram-negative rods after the introduction of ertapenem onto a hospital formulary. Abstracts of the Forthy-foupth Infections Disease Society of America Toronto, Canada. Abstract 280, 2006. p. 98.